Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-199 + tamoxifen in metastatic ER-positive breast cancer
ACTRN12615000702516Phase 2Completed
- Sponsor
- Melbourne Health
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax and tamoxifen in breast cancer (2 arms), sponsored by Melbourne Health. Primary endpoint: Maximum tolerated dose. Started Aug 2015; status: completed.
02
Drugs
venetoclaxtamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12615000702516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000702516.